Overview

Biomanufacturing has become a vital pillar of Tianjin's modern industrial system, becoming both a strategic emerging industry and a key future sector under focused development.

Today, Tianjin stands as Asia's largest production base for insulin and industrial enzymes, as well as China's largest base for amino acid active pharmaceutical ingredients.

The city is home to a strong cluster of leading and high‑growth enterprises — including Asymchem, CanSino Biologics, Tianjin Pharmaceutical Holdings, Ringpu Biology, and Juventas Cell Therapy — forming a dynamic industrial ecosystem. A multi‑zone development pattern has taken shape, with Binhai New Area as the core hub and Wuqing, Beichen, Xiqing, and Jinnan each cultivating distinctive strengths.

As major cities across China race to expand their biomanufacturing capabilities, Tianjin has secured a spot at the forefront of R&D. Anchored by the Tianjin Institute of Industrial Biotechnology of the Chinese Academy of Sciences, alongside Tianjin University, Nankai University, and Tianjin University of Science and Technology, the city has built a robust innovation engine that places it firmly in the leading national tier.